An observational study suggests inferiority of rituximab vs ocrelizumab.
Multiple B cell therapies for multiple sclerosis (MS) currently are available, with limited head-to-head studies to compare their effectiveness. For this retrospective, observational cohort study, investigators included 710 patients with MS treated with ocrelizumab who were propensity score–matched with 186 patients treated with rituximab. The noninferiority margin was set at an annualized relapse rate (ARR) ratio of 1.63.
During a mean follow-up of 1.4 years, the ARR was 0.20 on rituximab vs. 0.09 on ocrelizumab (ARR ratio, 1.8; 95% confidence interval, 1.4–2.4). Thus, noninferiority of rituximab to ocrelizumab was not shown.
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)